Results for xenografts translation from English to Slovenian

transplantation with xenografts.
presaditev s ksenotransplantati.

no anti-tumour effects of panitumumab were observed in human tumour xenografts lacking egfr expression.
pri človeških tumorskih ksenotransplantatih, ki niso imeli eksprimiranega egfr, niso ugotovili protitumorskih učinkov panitumumaba.

sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis.
zavira rast širokega spektra humanih tumorskih presadkov pri atimičnih miših, hkrati pa zmanjšuje tumorsko angiogenezo.

crizotinib demonstrated antitumour efficacy, including marked cytoreductive antitumour activity, in mice bearing tumour xenografts that expressed alk fusion proteins.
krizotinib je pokazal protitumorsko učinkovitost, vključno z izrazito citoredukcijsko protitumorsko aktivnostjo, pri miših s heterolognimi tumorskimi presadki, ki so izrazili alk fuzijske beljakovine.

in particular, treatment of tumour xenografts with nintedanib led to a rapid reduction in tumour micro vessel density, pericytes vessel coverage and tumour perfusion.
Še zlasti je zdravljenje tumorskih ksenograftov z nintedanibom hitro zmanjšalo gostoto mikrožilja v tumorju in njegovo perfuzijo ter prekritje žil s periciti.

recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals.
rekombinantni interferon alfa-2b je v raziskavah na živalskih in človeških celičnih kulturah, pa tudi na človeških tumorskih ksenopresadkih na živalih, pokazal antiproliferativne učinke.

the combination of dabrafenib with trametinib has shown anti- tumour activity in braf v600 mutation positive melanoma cell lines in vitro and delays the emergence of resistance in vivo in braf v600 mutation positive melanoma xenografts.
kombinacija dabrafeniba in trametiniba je pokazala protitumorsko aktivnost pri melanomskih celičnih linijah z mutacijo braf v600 in vitro, in vivo pa zakasni nastanek rezistence pri heterolognih melanomskih presadkih z mutacijo braf v600.

in vivo, pazopanib inhibited vegf-induced vegfr-2 phosphorylation in mouse lungs, angiogenesis in various animal models, and the growth of multiple human tumour xenografts in mice.
in vivo je pazopanib zaviral z žilnim endotelijskim rastnim faktorjem povzročeno fosforilacijo vegfr-2 v pljučih miši, angiogenezo pri različnih živalskih modelih in rast multiplih humanih tumorskih ksenogenskih presadkov pri miših.

in human cancer xenograft models capecitabine demonstrated a synergistic effect in combination with docetaxel, which may be related to the upregulation of thymidine phosphorylase by docetaxel.
v ksenografskih modelih raka pri ljudeh je imel kapecitabin v kombinaciji z docetakselom sinergistični učinek, kar je lahko povezano z uravnavanjem timidin fosforilaze zaradi docetaksela.